Contraceptive Technology Update – October 1, 2016
October 1, 2016
View Issues
-
Updates Issued for US MEC, SPR — What Do the Changes Mean?
Time to update your practice. The U.S. Medical Eligibility Criteria for Contraceptive Use, 2016 (US MEC 2016) and the U.S. Selected Practice Recommendations for Contraceptive Use, 2016 (US SPR 2016) have new information.1,2
-
Get the Latest Guidance on Zika Virus In the Family Planning Setting
Clinicians can get up to speed on the latest strategies for Zika virus prevention, as well as implement the latest guidance surrounding Zika in the family planning setting, with new webinars hosted by the American College of Obstetricians and Gynecologists (ACOG) and the CDC.
-
Combined Hormonal Contraception and Migraine — Add Clinical Information to Your Practice
What do you know when it comes to prescribing combined hormonal methods for women with migraines? A new two-part Association of Reproductive Health Professionals webinar series, “Migraines & the Female Patient,” offers information on the epidemiology of migraines and how to counsel affected women on their contraceptive options.
-
Counsel on Convenience and Effectiveness Of Immediate Postpartum LARC
Unplanned pregnancies can happen in the postpartum period. Data indicate 40-57% of women report having unprotected intercourse before the routine six-week postpartum visit.1,2 The American College of Obstetricians and Gynecologists (ACOG) has just issued a new committee opinion on the use of long-acting reversible contraception (LARC) in the postpartum period to help stem such pregnancies.3
-
The Trajectories of Vasomotor Symptoms Eyed Across the Menopausal Transition
Most women will get hot flashes or night sweats at some point during menopause. Research indicates 42% to 79% of women experience vasomotor symptoms (VMSs) during the menopausal transition.1-4 Just-published findings show that women fit into four distinct groups when it comes to having hot flashes and night sweats, which offers potential ramifications for therapy and prevention of future health conditions, according to research led by the Graduate School of Public Health at the University of Pittsburgh.5
-
U.S. Preventive Services Task Force Recommends Against Genital Herpes Screening
The CDC estimates that about one in six U.S. residents ages 14-49 has genital herpes.1 In new draft guidance, the U.S. Preventive Services Task Force (USPSTF) recommends against using current blood tests to screen for genital herpes in people with no signs or symptoms of infection, including adolescents and adults, as well as pregnant women.2